STOCK TITAN
  1. Home
  2. News
  3. SABS

SAB Biotherapeutics, Inc. - SABS STOCK NEWS

Welcome to our dedicated page for SAB Biotherapeutics news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB Biotherapeutics stock.

SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company pioneering in the development and commercialization of fully human polyclonal antibodies using its proprietary DiversitAb™ platform. Unlike traditional methods involving human plasma or serum, SAB leverages genetically engineered transchromosomic cattle (Tc Bovine™) to produce large volumes of human antibodies (immunoglobulin G) in response to specific antigens.

The company's core technologies aim to provide novel therapies for a wide range of immune and autoimmune disorders, including its lead asset SAB-142, which targets type 1 diabetes (T1D). SAB-142 is a human anti-thymocyte immunoglobulin designed to modulate the body's immune response, potentially delaying the onset and progression of T1D. This innovative approach has shown promise in early clinical trials, with Phase 1 studies demonstrating safety and biological activity without the adverse reactions commonly associated with animal-derived therapies.

Recent achievements include the FDA granting Breakthrough Therapy and Fast Track Designations to SAB-176, a fully human polyclonal antibody targeting multiple strains of Influenza A and B. This reflects the potential of SAB's platform to address unmet medical needs swiftly and effectively.

SAB is actively pursuing multiple projects and partnerships to expand its clinical pipeline. Notable collaborations include a pharmacokinetic and safety study for SAB-176, conducted in partnership with the Henry Jackson Foundation and the NMRC Clinical Trials Center. Additionally, SAB’s ongoing Phase 1 clinical trial for SAB-142 has successfully completed dosing the third cohort with no observed serum sickness.

Financially, SAB reported positive results for Q1 2024, with sufficient cash reserves expected to fund operations into 2026, assuming the exercise of outstanding Tranche B warrants. The company's strategic relocation of its headquarters to Miami, FL, and the recent appointment of Dr. Jay Skyler to its Board of Directors underscore its commitment to T1D research and treatment.

SAB Biotherapeutics continues to engage with the scientific and investment communities, providing regular updates on its progress and maintaining transparency in its forward-looking statements. As a pioneer in biopharmaceutical innovation, SAB is poised to make significant contributions to the treatment of immune and autoimmune disorders.

News

SAB Biotherapeutics Announces Executive Leadership Change

Rhea-AI Summary
SAB Biotherapeutics, Inc. announced the appointment of Samuel J. Reich as the new CEO, effective February 2, 2024. Eddie J. Sullivan, Ph.D., will continue as President and a member of the Board of Directors. The company aims to progress its lead product candidate SAB-142 through milestones towards approval, with a focus on delaying the onset or progression of type 1 diabetes (T1D).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
management
-
News

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after conducting a 1-for-10 reverse split of its common shares. The Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on January 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
News

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced a reverse stock split of its outstanding shares of common stock, effective January 5, 2024, to increase per share trading price and maintain Nasdaq listing compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
News

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) has initiated the first-in-man Phase 1 clinical study of SAB-142, a fully-human anti-thymocyte immunoglobulin (ATG) targeting immune cells involved in the destruction of insulin-producing pancreatic beta cells to potentially preserve beta cell function. The company is pursuing IND and CTA filings with U.S. FDA and EMA in 2024 to advance SAB-142 into a Phase 2b study for disease-modification of Type 1 Diabetes (T1D). The Phase 1 trial in Australia aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAB-142 in healthy volunteers and participants with T1D, with a focus on establishing Proof of Biological Activity (POBA) for SAB-142.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
clinical trial
-
News

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

Rhea-AI Summary
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Katie Ellias to the Company’s Board of Directors. Ms. Ellias, a Managing Director at the JDRF T1D Fund LLC, brings extensive experience in T1D-oriented therapies. With approximately $200 million in assets, the T1D Fund has invested in SAB. Ms. Ellias' expertise and impact are expected to benefit SAB as it aims to change the T1D treatment paradigm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
management
-
News

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Rhea-AI Summary
SAB Biotherapeutics, Inc. (NASDAQ: SABS) announced the funding of the second tranche of a previously-announced financing, raising total aggregate proceeds to date of $67.1 million. The funds will support the development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditions. Participating investors include Sessa Capital, BVF Partners, RTW Investments, Marshall Wace, ATW, and the JDRF T1D Fund. The investment will move human trials forward for SAB’s lead research program, which was recently granted approval by Australian authorities to begin a first-in-human Phase 1 clinical study of SAB-142.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
News

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) has raised a combined $67.1M in a private placement and Tranche warrant exercise with a syndicate of leading investors. The company also received approval from the Human Research Ethics Committee (HREC) to commence a First-in-Human Phase 1 clinical trial investigating SAB-142 in Australia. Additionally, Michael G. King Jr. has been appointed as the new Chief Financial Officer. The company reported financial results for the third quarter of 2023 and provided a company update, highlighting the advancement of SAB-142, their T1D immunotherapy, and the addition of senior expertise to the team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
earnings
-
News

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) announces CEO's presentation at 35th Annual Piper Sandler Healthcare Conference to discuss the development of hIgG for type 1 diabetes. The event aims to gather industry leaders and investors for trend analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
-
News

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Rhea-AI Summary
SAB Biotherapeutics appoints Michael G. King Jr. as Chief Financial Officer. King brings over 25 years of experience as a biotech equity research analyst and senior advisor. He will replace Russell Beyer, who will remain a senior advisor until the end of the year. King's expertise will contribute to SAB's goal of developing disease-modifying treatments for type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
management
News

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Rhea-AI Summary
SAB Biotherapeutics receives approval for Phase 1 clinical study of SAB-142 in Australia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.5%
Tags
clinical trial

FAQ

What is the current stock price of SAB Biotherapeutics (SABS)?

The current stock price of SAB Biotherapeutics (SABS) is $4.65 as of December 20, 2024.

What is the market cap of SAB Biotherapeutics (SABS)?

The market cap of SAB Biotherapeutics (SABS) is approximately 36.1M.

What is SAB Biotherapeutics, Inc.?

SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company developing fully human polyclonal antibodies using its proprietary DiversitAb™ platform.

What is the DiversitAb™ platform?

The DiversitAb™ platform uses genetically engineered transchromosomic cattle (Tc Bovine™) to produce large volumes of fully human antibodies in response to specific antigens, avoiding the need for human plasma or serum.

What is SAB-142?

SAB-142 is SAB's lead asset, a human anti-thymocyte immunoglobulin targeting type 1 diabetes (T1D), aiming to delay the onset and progression of the disease.

What recent achievements has SAB Biotherapeutics reported?

SAB-176 received Breakthrough Therapy and Fast Track Designations from the FDA, and the company completed dosing the third cohort in its Phase 1 trial for SAB-142 without observed serum sickness.

Who are SAB's key partners?

SAB collaborates with the Henry Jackson Foundation and the NMRC Clinical Trials Center for its pharmacokinetic and safety studies, among other partnerships.

Where is SAB Biotherapeutics headquartered?

SAB Biotherapeutics recently relocated its corporate headquarters to Miami, FL while retaining its Research and Development Campus in South Dakota.

What is the financial outlook for SAB Biotherapeutics?

Based on current plans, SAB has sufficient cash to fund operations into 2026, assuming the exercise of all outstanding Tranche B warrants.

How does SAB-142 differ from rabbit-derived ATG?

SAB-142 is a fully human immunoglobulin designed to avoid the adverse immune reactions associated with rabbit-derived ATG, making it safer for long-term use in treating T1D.

What is the focus of SAB's current clinical trials?

SAB's clinical trials predominantly focus on demonstrating the safety, tolerability, and efficacy of its human antibodies, particularly in treating type 1 diabetes and influenza.

How can I learn more about SAB Biotherapeutics?

For more information, you can visit SAB's website at www.SAB.bio and follow them on Twitter and LinkedIn.

Stock SABS logo
SAB Biotherapeutics, Inc.

Nasdaq:SABS

SABS Rankings

#5051 Ranked by Market Cap
N/A Ranked by Dividends

SABS Stock Data

36.09M
7.46M
19.15%
34.25%
0.43%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
MIAMI BEACH